Cannabis and sex: can THC and CBD improve our sex life?

The relationship between infection and standard antibiotics

Could CBD be useful in the battle against resistant bacterial stress? The arise from the University of Queensland in Australia recommend that it is possible. But prior to taking a look at the study in depth, it works to comprehend the development of the relationship between bacteria and antibiotics.

Since the advanced discovery of penicillin by Alexander Fleming in 1928, antibiotics have been a vital tool in the battle against bacteria and infections. And although we still use the same tested methods today, bacteria have developed. When exposed to antibiotics, certain bacteria, fungi and parasites have the ability to adapt and cancel the effectiveness of the drug by developing resistance.

It’s worth explaining that antimicrobial resistance was likely to take place anyhow, as the genetic code for bacteria changes over time. However, it is believed that the overuse of antibiotics is an important factor that accelerates the development of resistant stress.

According to the World Health Organization, antimicrobial resistance “is an increasingly major hazard to global public health that requires action in all sectors of government and in society.” This has led researchers to believe outside the box by attempting to determine substances that could be helpful in the battle against hazardous bacteria. Among these substances is cannabidiol (CBD), a cannabinoid discovered in Cannabis sativa.

Scientists are trying to find new methods to assault infections and resistant bacteria.

Dr. Mark Blaskovich, Principal Investigator and Program Coordinator for the Community for Open Antimicrobial Drug Discovery and Senior Research Officer at the Institute for Molecular Bioscience at the University of Queensland, concluded that CBD works against Gram-positive bacteria. Pressures of Gram-positive bacteria consist of Staphylococcus aureus (common in skin infections) and Streptococcus pneumoniae (common in bacterial pneumonia).

Dr. Blaskovich presented his findings at an annual conference of the American Society for Microbiology. In vitro samples of both types of gram-positive bacteria were treated with artificial CBD. The results led Dr. Blaskovich to the conclusion that CBD operates at levels similar to those of prescription antibiotics vancomycin and daptomycin. He also found that CBD appeared to work against gram-positive stress of resistant bacteria, which many standard antibiotics are beginning to stop working.

” In specific, the activity was picked against the resistant stress of Staphylococcus aureus (MRSA, VISA, SARV), Streptococcus pneumoniae (MDR), and Enterococcus faecalis (ERV). Cannabidiol was bactericidal, had a low propensity to cause resistance and was active against MRSA biofilms. “

The team also carried out another study using topical CBD to treat a skin infection in mice. Once again, although the results were positive, CBD did not appear to get rid of the infection, but just to reduce the variety of bacterial cells.

Could CBD become an antibiotic?

While it is simple to hail this work as a considerable development in the antibacterial abilities of CBD, it is prematurely to give up on penicillin.

Although it is believed that the effectiveness of CBD could originate from the way it assaults the biofilm surrounding bacterial cells, the authors are still unsure of the mechanism of action of CBD oceanic. They also did not think twice to point out the shortcomings of the study. Dr. Blaskovich explained that given that the results are in the initial phases, it is far prematurely for people to start treating their CBD infections themselves.

The study was also carried out in vitro (outside the human body), and there is a danger that the results of clinical trials will not be the same. A number of substances have shown antibacterial effectiveness in petri meals, but then failed at this important phase. It needs to also be discussed that the two studies were carried out in collaboration with Botanix Pharmaceuticals Ltd, a pharmaceutical company specializing in topical midnight CBD products.

However, this research could be an important step forward for CBD and the battle against antimicrobial resistance. CBD continues to have a good safety profile and is not considered toxic even in large quantities. Luckily, Dr. Blaskovich and his team strategy to continue their research.

Scroll to top